AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04090281 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: CYP2C19 genotyping
Description: Upon hospital discharge, patients will undergo CYP2C19 genotyping to guide initial P2Y12 inhibitor selection. At 14 days, post discharge, patients will undergo on treatment platelet reactivity phenotyping to further guide deescalation of P2Y12 inhibitor therapy
Study NCT04664920 — intervention group
Intervention type: DEVICE
Intervention: exergame
Description: motor-cognitive training device
Study NCT02642887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mTA + SCTG
Description: These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
Study NCT04077242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic Fallopian tube assessment using the Parryscope technique
Description: A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present \[10\]. At least 30 seconds of observation per ostia is performed if patency is not observed.
Study NCT04077242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic Fallopian tube assessment using the Tubal flow technique
Description: a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia.
Study NCT01557582 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ventripoint Medical System
Description: The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.~Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images.
Study NCT02717078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Therapy
Description: The intervention for both study groups will be a change in diet.
Study NCT02717078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Therapy
Description: The intervention for both study groups will be a change in diet.
Study NCT03952585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT03952585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT03952585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03952585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03952585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT03952585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03952585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03952585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03952585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Receive FDG
Study NCT03952585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive FDG
Study NCT03952585 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT
Study NCT03952585 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT
Study NCT03952585 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT04035109 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anakinra
Description: A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered after nasal allergen challenge.
Study NCT04035109 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Preservative-free 0.9% sodium chloride (Placebo)
Description: A single subcutaneous injection of sodium chloride (placebo) will be administered after nasal allergen challenge.
Study NCT04035109 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: House dust mite allergen
Description: Standardized house dust mite (Dermatophagoides farinae) allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to house dust mite (determined by skin prick testing) will undergo intranasal challenge with house dust mite allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
Study NCT04035109 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cat hair allergen
Description: Standardized cat hair allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to cat hair (determined by skin prick testing) will undergo intranasal challenge with cat hair allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
Study NCT00963131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antioxidants tablets
Description: vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
Study NCT00963131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: antioxidants tablets
Description: vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
Study NCT00167648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide or goserelin
Description: Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
Study NCT00167648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Description: Estradiol patches, six at 0.1 mg each, changed every 3-4 days
Study NCT01796483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clonidine (Catapressan)
Description: Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG
Study NCT01796483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine (Catapressan)
Description: Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG
Study NCT01796483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo 90 minutes before EEG
Description: Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
Study NCT01796483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 90 minutes before EEG
Description: Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
Study NCT03308786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Interleukin-2
Description: Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for four consecutive days(cycle) every 8 weeks for 8 cycles
Study NCT03374969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-Up
Description: Attachment and Biobehavioral Catch-up (ABC) is a 10-session, weekly intervention delivered in the family's home. ABC addresses three primary issues. First, young children who have experienced early adversity are especially in need of nurturance and parents who behave in synchronous ways and delight in them. Next, when parents behave in frightening ways, it is difficult for children to look to them for reassurance when distressed. This can be particularly difficult for children who have experienced early adversity. Therefore, this intervention helps parents learn how to: 1) behave in nurturing ways when children are distressed; 2) behave in synchronous, delighted ways when children are not distressed; and 3) avoid behaving in frightening or intrusive ways. Interventionists are provided with a manualized protocol, but tailor specific session content to each family's needs. Sessions are videotaped, both for playback to families, and for supervision.
Study NCT03374969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Education for Families
Description: Developmental Education for Families (DEF) is a 10-session, weekly intervention delivered in the family's home. DEF focuses on enhancing gross and fine motor skills, cognition and language development. The age-based protocols (i.e., 6-24 months,) provide information about the developmental themes of focus for each week and suggest activities to enhance the target skills for that week. However, the protocols do not provide a direct script with which to conduct the sessions. Interventionists tailor the developmental program session to the needs of the child and family by considering the child's current gross, fine, cognitive and language skills and creatively preparing several activities that will address the session topics.
Study NCT02850107 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic HawkOne® or TurboHawk™
Description: Use of FDA Cleared Directional Atherectomy (DA) Devices. Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System. DA followed by DCB will be performed in all enrolled subjects.
Study NCT02850107 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic IN.PACT® Admiral® DCB
Description: FDA Approved Drug Coated Balloon (DCB) Technology. Medtronic IN.PACT® Admiral® DCB will be used after DA.
Study NCT02850107 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic Spider™ Distal Protection Device (DPD)
Description: It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).
Study NCT02850107 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Volcano Visions® PV .014 IVUS catheter
Description: Lesion IVUS assessment using the Volcano Visions® PV .014 IVUS catheter will be required in all cases.
Study NCT02850107 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nitinol Stent Placement
Description: Only FDA approved nitinol stents can be used if provisional stenting is required.
Study NCT03196856 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance and Plyometric Exercise
Description: 12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training
Study NCT03196856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance and Plyometric Exercise
Description: 12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training
Study NCT03196856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greek Yogurt (0% Plain)
Description: 200g 3x/day for 12 weeks.
Study NCT03196856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Study Designed Supplement
Description: Iso-energetic to yogurt. 3x/day for 12 weeks.
Study NCT01138774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Double blind dietary intervention with EPA and lipoic acid
Description: Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
Study NCT01138774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Double blind dietary intervention with EPA and lipoic acid
Description: Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
Study NCT03676192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-16
Description: 15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
Study NCT03676192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: 15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
Study NCT03698409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preserved saline in reconstitution of Botox
Description: The intervention consists of using 4 ml of preserved saline for the reconstitution of OnabotuliniumtoxinA prior to its use in subjects with chronic migraine.
Study NCT00134030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT00578617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Diltiazem 180-240mg
Study NCT00578617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Verapamil 180-240mg
Study NCT00578617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Digoxin 0.125mg
Study NCT00578617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm Control
Description: Propafenone 450mg
Study NCT00578617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Flecainide 200mg
Study NCT00134030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00134030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00134030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00134030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00134030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT00134030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IV
Study NCT00134030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT00134030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: Given subcutaneously
Study NCT00134030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00134030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00134030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00134030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00134030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo amputation or limb salvage surgery
Study NCT00134030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo amputation or limb salvage surgery
Study NCT04259320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beeswax containing barrier
Description: Use beeswax containing barrier on each nipple after each breastfeeding.
Study NCT04259320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Breast milk
Description: Apply breast milk on each nipple and areola after each breastfeeding.
Study NCT01223131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous
Study NCT01223131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous
Study NCT04967378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEPPI
Description: 10 weekly individual sessions, 90 minutes each, at the participants' homes. The content of sessions includes psychoeducation, cognitive training, psychotherapeutic intervention, and compensatory strategy training.
Study NCT01538511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted
Study NCT01538511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
Study NCT01323959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BoostrixTM Polio
Description: Single dose, intramuscular administration.
Study NCT00578617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Sotalol 240mg
Study NCT00578617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Dofetilide 500mcg
Study NCT00578617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Amiodarone 200mg
Study NCT00578617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Quinidine 600-900mg
Study NCT04376385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GROw: An Internet based Self Applied Treatment Program for Prolonged Grief Disorder (PGD)
Description: It is a self-applied treatment through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is 8-10 weeks. A support call will be made a week (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided.~Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
Study NCT02754011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of ribociclib + capecitabine
Description: RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
Study NCT00872417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)
Description: use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
Study NCT00872417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: second line ARV therapy (3TC+TDF+LPV/RTV)
Description: Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
Study NCT02046616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 162 mg will be administered subcutaneously QW.
Study NCT02046616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
Study NCT02046616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Biologic DMARDs
Description: Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
Study NCT02153606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin Suppository
Description: The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
Study NCT02153606 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Suppository
Description: Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
Study NCT02595398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg CLS-TA Suprachoriodal Injection
Description: CLS-TA, 40 mg/mL (4 mg in 100 µL), administered as a single injection at 2 timepoints
Study NCT02595398 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Sham procedure administered at 2 timepoints